구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Inotuzumab ozogamicin (Inotuzumab ozogamicin) Pfizer·Precursor Cell Lymphoblastic Leuke… 53 trials·t½ 12.3 h |
|---|---|
Overview Program | Inotuzumab ozogamicin |
Overview Company | Pfizer |
Overview Modality | ADC |
Overview Target | Precursor Cell Lymphoblastic Leukemia-Ly |
Overview Indication | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Linker | linker, or payload that have limited their development |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen |
MoA Biomarker | CD19 expression, whereas cytoplasmic CD22 expression |
PK/PD Half-life | 12.3 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia (31 patients [84%]), being the most common |
Toxicology CRS | Reported |
Clinical Safety signal | thrombocytopenia (31 patients [84%]), being the most common |
Clinical Reported PFS | 5.0 |
Clinical Reported OS | 7.7 |
Clinical Result source | ClinicalTrials.gov NCT01564784 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT01564784 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Inotuzumab ozogamicin (Inotuzumab ozogamicin) Pfizer·Precursor Cell Lymphoblastic Leuke… 53 trials·t½ 12.3 h |
|---|---|
Overview Program | Inotuzumab ozogamicin |
Overview Company | Pfizer |
Overview Modality | ADC |
Overview Target | Precursor Cell Lymphoblastic Leukemia-Ly |
Overview Indication | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Linker | linker, or payload that have limited their development |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen |
MoA Biomarker | CD19 expression, whereas cytoplasmic CD22 expression |
PK/PD Half-life | 12.3 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia (31 patients [84%]), being the most common |
Toxicology CRS | Reported |
Clinical Safety signal | thrombocytopenia (31 patients [84%]), being the most common |
Clinical Reported PFS | 5.0 |
Clinical Reported OS | 7.7 |
Clinical Result source | ClinicalTrials.gov NCT01564784 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT01564784 |
추천 비교
추천 비교